Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Persistence of SARS-CoV-2 antibodies over 18 months following infection: UK Biobank COVID-19 Serology Study.

Bešević J. et al, (2023), Journal of epidemiology and community health

Structural and non-coding variants increase the diagnostic yield of clinical whole genome sequencing for rare diseases.

Pagnamenta AT. et al, (2023), Genome medicine, 15

Integrative GWAS and co-localisation analysis suggests novel genes associated with age-related multimorbidity

West CE. et al, (2023), Scientific Data, 10

Alterations in the gut microbiome implicate key taxa and metabolic pathways across inflammatory arthritis phenotypes.

Thompson KN. et al, (2023), Science translational medicine, 15

Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK

Wei J. et al, (2023), Nature Communications, 14

Supportive Evidence For The Potential For Novel Biodiscovery In Osteoarthritis Through The Stepup Oa Consortium

Perry TA. et al, (2023), Osteoarthritis and Cartilage, 31, S353 - S354

Pathogenic Interleukin-10 Receptor Alpha Variants in Humans — Balancing Natural Selection and Clinical Implications

Aschenbrenner D. et al, (2022), Journal of Clinical Immunology

COMBATdb: a database for the COVID-19 Multi-Omics Blood ATlas

Wang D. et al, (2022), Nucleic Acids Research

Symptoms and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Positivity in the General Population in the United Kingdom

Vihta KD. et al, (2022), Clinical Infectious Diseases, 75, e329 - e337

Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom

Vihta1 KD. et al, (2022), Clinical Infectious Diseases

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines

Wei J. et al, (2022), Nature Medicine, 28, 1072 - 1082

An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status

Lumley SF. et al, (2022), Clinical Infectious Diseases, 74, 1208 - 1219

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

Ahern DJ. et al, (2022), Cell, 185, 916 - 938.e58

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines

Wei J. et al, (2022), Nature Medicine

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Abani O. et al, (2022), The Lancet, 399, 665 - 676

Fragment Hotspot Mapping to Identify Selectivity-Determining Regions between Related Proteins.

Smilova MD. et al, (2022), Journal of chemical information and modeling, 62, 284 - 294

Target 2035-update on the quest for a probe for every protein

Mueller S. et al, (2021), RSC MEDICINAL CHEMISTRY

Stringent thresholds in SARS-CoV-2 IgG assays lead to under-detection of mild infections

Eyre DW. et al, (2021), BMC Infectious Diseases, 21

Symptoms and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Positivity in the General Population in the United Kingdom

Vihta K-D. et al, (2021), Clinical Infectious Diseases

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population

Wei J. et al, (2021), Nature Communications, 12

Load More

1
2
3
4
5

Include forthcoming?